PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina. As of December 8, 2021, PPD, Inc. operates as a subsidiary of Thermo Fisher Scientific Inc.
Visit company website
5 years, 4 months ago
PPD, Inc is currently in a long term uptrend where the price is trading 17.9% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.9.
Based on the above factors, PPD, Inc gets an overall score of 2/5.